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Background: Prostate cancer is the most commonly diagnosed malignancy in men in Sweden and Geneva, and
the third most common in men in Singapore. This population-based study describes trends in the incidence and
mortality rates of prostate cancer in Singapore, Sweden and Geneva (Switzerland) from 1973 to 2006 and explores
possible explanations for these different trends.
Methods: Data from patients diagnosed with prostate cancer were extracted from national cancer registries in
Singapore (n = 5,172), Sweden (n = 188,783) and Geneva (n = 5,755) from 1973 to 2006. Trends of incidence and
mortality were reported using the Poisson and negative binomial regression models. The age, period and birth-
cohort were tested as predictors of incidence and mortality rates of prostate cancer.
Results: Incidence rates of prostate cancer increased over all time periods for all three populations. Based on the
age-period-cohort analysis, older age and later period of diagnosis were associated with a higher incidence of
prostate cancer, whereas older age and earlier period were associated with higher mortality rates for prostate
cancer in all three countries.
Conclusions: This study demonstrated an overall increase in incidence rates and decrease in mortality rates in
Singapore, Sweden and Geneva. Both incidence and mortality rates were much lower in Singapore. The period
effect is a stronger predictor of incidence and mortality of prostate cancer than the birth-cohort effect.Background
Prostate cancer is the most commonly diagnosed malig-
nancy in men in Sweden [1] and Geneva [2], and the
third most common in men in Singapore [3]. Prostate
cancer rates in Asian men in countries such as China [4]
and Japan [5] are substantially lower than in Caucasians,
however, the sharpest increase in prostate cancer inci-
dence has most recently been observed in Asian coun-
tries [6], for example, incidence rates in Singapore have
quadrupled over the past decade [3]. In Europe and the* Correspondence: ephcse@nus.edu.sg
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reproduction in any medium, provided the orUS, prostate cancer incidence rates have also increased
and are most likely due to an increased awareness of
prostate-related symptoms, improved access to health
care, and increased diagnostic activity through prostate-
specific antigen (PSA) testing [7].
PSA testing received US Food and Drug Administra-
tion approval as a monitor for treatment response in
1986 and was subsequently approved as a screening aid
for diagnosis in 1994 [8]. PSA testing has subsequently
contributed to a doubling in the incidence rates of pros-
tate cancer in the US between 1986 and 1992 [9]. Simi-
larly, after PSA screening became available in the Nordic
countries circa. 1990, rapid increases in PSA testing
were also shown to be associated with sharp increases in
prostate cancer incidence [10].td. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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rates of prostate cancer have declined in several coun-
tries [11,12]. A comparison of the incidence and morta-
lity rates between Singapore and European countries,
such as Sweden and Geneva, could reveal important
insights into these trends. Thus, our study aimed to
compare the incidence and mortality rates of prostate
cancer in Singapore, Sweden and Geneva.
Methods
Data source
Incidence and mortality data (1973–2006)
Singapore Comprehensive population-based cancer
registration in Singapore began in January 1968, with the
aim of providing current information on cancer patterns
and trends. Data was obtained from different sources,
namely notifications by physicians, pathology records,
hospital records, and death certificates. Population based
data for incidence and mortality rates for Singapore was
taken from the Singapore Cancer Registry, National
Registry of Diseases Office (NRDO) (n = 5,172). The
denominators for incidence and mortality were the total
number of person-years from the Singapore resident
population based on the Singapore Population Census
2000 updated reports [13].
Sweden Sweden was selected as a country of compari-
son as it has one of the highest incidence rates of
prostate cancer globally [14]. Incidence and mortality
population based data for Sweden was extracted from
the NORDCAN database (http://www-dep.iarc.fr /nordcan/
English/frame.asp) (n=188,783). This database contains
data on the prevalence, incidence and mortality of 41 can-
cers, including prostate cancer, from each Nordic countries’
national cancer and mortality registries over the past
60 years [15] and which is updated approximately twice a
year. Coverage of incident cases in each registry was previ-
ously reported to be close to 100% [16,17]. Data was
collected from multiple sources, including physicians, hos-
pitals, institutions with hospital beds, pathological and cyto-
logical laboratories, and by linkages with administrative
health/disease registers. Our study contained incidence and
mortality data extracted from the NORDCAN database
over the period 1973 to 2006.
Geneva Geneva was selected for comparison due the
availability of a complete dataset for analysis. Population
based data on incidence and mortality for Geneva was
used over the period 1973 to 2006. Data on incident
cases and deaths were obtained from the Geneva Cancer
Registry (Institute for Social and Preventive Medicine,
Geneva University, Geneva, Switzerland) and the ‘Office
Cantonal de la Population’ respectively (n = 5,755). TheGeneva Cancer Registry recorded all incident cancers
occurring in the population of the canton (approxi-
mately 465,000 inhabitants in 2007) since 1970. Informa-
tion was collected from various sources [18] and is
considered accurate with <2% of cases recorded from
death certificates only [19,20]. Trained tumor registrars
systematically extracted data from medical and labora-
tory records. Cause of death was established from cli-
nical files and/or information from physicians.
Statistical analysis
Incidence rates and mortality rates were defined as the
number of new cases and the number of deaths, respec-
tively, in a given period for a specific population. To
adjust for the differences in the age structure and to
account for the strong influence of age on the risk of
cancer, the incidence rates and mortality rates were age-
standardised to the world standard million population
and expressed as 100,000 person years for persons aged
45 years and above. Data were analysed using five year
age groups (45–49, 50–54, . . .70-74, 75+ years) for all
three countries. As those aged 45 years and above con-
stituted only 26% in the world standard million popula-
tion, we recalibrated the weighting to 100% based on the
respective weights of each age group.
The number of incident cases and deaths were
assumed to follow a Poisson distribution and hence we
used log-linear Poisson modeling of cases based on age
and year of diagnosis (period) and year of birth (birth-
cohort). When over-dispersion (variance greater than
the mean) was detected while modeling the incidence or
mortality, a negative binomial distribution was used [21]
instead of the original Poisson distribution, as a negative
binomial distribution has a larger variance than a Pois-
son distribution.
A limitation of using only age-standardised rates to de-
scribe the trends in incidence and mortality rates is that
this does not account for period and birth-cohort effects.
Use of the age-period (AP) and age-birth-cohort (AC)
models was applied to disentangle the separate effects of
period of diagnosis and birth-cohort on incidence and
mortality. Period effects tend to influence all individuals
simultaneously during a particular time period regardless
of their age, whilst birth-cohort effects are attributable
to certain factors related to the birth year. The analysis
was based on the generalized linear model approach. We
also considered the scenario where the effects of period
and birth-cohort in AP and AC models, respectively,
were assumed to be linear and hence inseparable. In such
cases, the combined linear model is referred to as the
age-drift model [22]. It is well established that there is a
linear dependency between age, period and birth-cohort
as the birth cohort can be computed by subtracting age
at diagnosis from the calendar period of diagnosis.
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of fit of the models. A non-significant p-value (> 0.05)
indicated a good fit. Difference in deviance and the like-
lihood ratio test were used to compare different models,
where a significant p-value indicates that the more com-
plicated model has significant improvement over the
simpler model. The deviance and change in deviance
due to cohort or period effects were compared to the
age-period-cohort (APC) model. The cohort effect was
tested in comparison to the AP and APC models and
likewise, the period effect was tested in comparison to
the AC and APC models.
The Akaike Information Criterion (AIC) was also
calculated to compare models with different comple-
xities that are not required to be nested within each
other, with smaller AIC values suggestive of a better
model fit [23]. We compared both the AP and AC
models with the APC model and selected the most
parsimonious model based on the likelihood ratio test
and AIC criteria.
Ethical approval for this study was granted by the
National University of Singapore IRB (approval number:
NUS-747).Results
Incidence
Overall, incidence rates increased during the period
1973 to 2006 (Figure 1, Table 1). Singapore had the low-
est age-standardised incidence rates for all 5-year
periods while Sweden had the highest, with the excep-
tion of the period 1993 to 2002. All three countries had
relatively sharper rises in incidence rates in the subse-
quent periods after 1993 to 1997, more so for Sweden
and Geneva compared to Singapore.
Higher age-specific incidence rates were found in older
age-groups and increased in the later years of diagnosisFigure 1 Age-standardised (world standard million population) prosta
stratified by country for Singapore, Sweden and Geneva.for all three countries (Figure 2). This increase was more
prominent in the age groups 55 to 74 years, with sharper
rises compared to younger age groups. In the age group
75 years and above, the rate of incidence increase was
less steep in the period after 1993 for both Singapore
and Sweden, despite increases in the overall age-specific
incidence rates. There was a decrease in incidence rates
for Geneva in the oldest age group since 1993. The age-
specific incidence rate overall for Geneva and Sweden was
approximately three times higher than that of Singapore.Mortality
Overall, Singapore had the lowest age-standardised mor-
tality rates over all periods measured (Figure 3, Table 1).
Both Geneva and Singapore experienced drops in mor-
tality rates from 1993 to 2006 whereas the mortality rate
for Sweden remained relatively constant (Figure 3).
Geneva had higher mortality rates as compared to
Sweden from 1973 to 1987, with a sharp decline there-
after. Singapore mortality rates showed a steady rise
from 1973 to 1997 and a sharp decline in the subsequent
two periods.
Higher age-specific mortality rates were found in the
older age groups for all three countries (Figure 4). In
both Singapore and Geneva, there was a drop in morta-
lity rates for the age group 65 years and above from
1993 to 2006 (Figure 4). In Sweden, the age-specific
mortality rates remained unchanged since 1973 for those
aged between 45 and 74 years. The oldest age group
(75+ years) had mortality rates following a U-shaped
pattern.APC modeling
The negative binomial distribution was preferred based
on the goodness of fit test when modeling incidence in
all three countries and mortality for Singapore andte cancer incidence rates per 5-year period (1973–2006)
Table 1 Age-adjusted incidence and mortality rates of all prostate cancers from 1973 to 2006, aged 20 and above for
Singapore, Sweden and Geneva
Country Period Incidence rate Mortality rate
(per 100,000 person years) (per 100,000 person years)
Total Rate Total Rate
Singapore 1973-1977 144 5.1 35 2.0
1978-1982 240 6.8 69 3.4
1983-1987 356 8.0 106 4.1
1988-1992 529 9.6 187 5.7
1993-1997 903 13.9 303 7.7
1998-2002 1357 17.6 434 9.3
2003-2006 1643 23.2 443 6.1
Sweden 1973-1977 17359 44.9 8516 21.6
1978-1982 19202 46.0 8400 19.5
1983-1987 22372 50.6 8795 18.9
1988-1992 25329 55.4 10341 20.9
1993-1997 28985 63.0 11411 21.6
1998-2002 37313 84.5 12287 21.4
2003-2006 38223 109.2 7625* 21.2*
Geneva 1973-1977 407 36.5 249 22.2
1978-1982 524 42.1 270 21.1
1983-1987 585 43.1 289 19.9
1988-1992 724 50.0 317 19.7
1993-1997 955 63.9 316 18.2
1998-2002 1345 86.4 279 14.5
2003-2006 1215 89.3 253 14.4
* Period for Sweden prostate mortality 2003–2005.
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modeling for mortality for Geneva. The likelihood ratio
test for incidence rates in all countries indicated that
both the AP model and the AC models were sufficient
in explaining the variation in the full APC model forFigure 2 Age-specific prostate cancer incidence rates (per 100,000 person-years) per 5-year period stratified by 5-year age group for
Singapore, Sweden and Geneva.Singapore (P-value = 0.999 (AP vs APC), 0.925 (AC vs
APC)), Sweden (P-value = 0.999, 0.975) and Geneva
(P-value = 0.800, 0.959) (Table 2).
Similarly, the likelihood ratio test for mortality rates
indicated that both the AP model and AC model were
Figure 3 Age-standardised (world standard million population) prostate cancer mortality rates per 5-year period (1973–2006) stratified
by country for Singapore, Sweden and Geneva.
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model for Singapore (P-value = 0.979, 0.869), Sweden
(P-value =0.999, 0.999) and Geneva (P-value =0.570, 0.258)
(Table 3).
Discussion
In general, the age-standardised incidence rates of pros-
tate cancer above the age of 50 years in all three coun-
tries increased between 1973 and 2006, and occurred at
a faster rate in Sweden and Geneva than in Singapore.
The sharper rise occurring in Sweden after the early
1990s is consistent with the increasing availability of
PSA testing [24] and may also be attributed to the more
frequent use of transurethral resection of the prostate
and invasive diagnostic procedures such as random bi-
opsies [25]. In Singapore, PSA screening is currently
recommended for males aged 50 to 75 years and with a
first degree relative diagnosed before age 65 years [26],
whereas approximately 1 in 2 males above age 50 yearsFigure 4 Age-specific prostate cancer mortality rates per 5-year (perin Sweden (56 % in 2007 [27]) and Geneva (55 % in
2005 [28]) had PSA screening. This could explain the
sharper rises in incidence rates after 1993 in Sweden and
Switzerland compared to Singapore. It is possible that
the continuous rise in incidence rates in Singapore may
represent a real increment of incident cases, given the
highly selective criteria for screening. A further potential
risk factor for these increasing incidence rates in Singa-
pore could be due to the adoption of a more Westernized
diet that generally has a higher intake of animal fats [29].
In comparison, soy based Asian diets have been shown to
provide some protection against prostate cancer [30,31].
As the upper limit for screening in Singapore [26],
Sweden [27] and Geneva [32] is up to 75 years, it is
expected that the rate of increase in incidence in the 75
+ year age group is slower (Figure 2). The higher overall
age-specific incidence rates for Geneva and Sweden
may be explained by the higher baseline incidence and
higher screening rates [28]. In addition, rapidly aging100,000 person-years) period stratified by 5-year age group.
Table 2 Goodness of fit and likelihood ratio test for incidence rates in Singapore, Sweden and Geneva
Goodness of fit
Singapore Sweden Geneva
(Negative binomial) (Negative binomial) (Negative binomial)
Model Res Dev* Df# AIC} P-value Res Dev DF AIC P-value Res Dev DF AIC P-value
Age (A) 31.5 42 473 0.882 24.4 42 817 0.632 38.3 42 500 0.986
Age-Drift (AD) 7.2 41 451 0.999 6.6 41 802 0.999 14.6 41 478 0.999
Age-Period (AP) 5.6 36 460 0.999 3.7 36 809 0.999 12.1 36 485 0.999
Age-Cohort (AC) 6.4 30 472 0.999 2.9 30 820 0.999 6.1 30 491 0.999
Full APC 5.0 25 481 0.999 2.0 25 829 0.999 5.1 25 500 0.999
Likelihood ratio test
Model Dev DF P-value Dev DF P-value Dev DF P-value
(H0vs H1)
AP vs APC 0.6 11 0.999 1.7 11 0.999 7.0 11 0.800
AC vs APC 1.4 5 0.925 0.9 5 0.972 1.0 5 0.959
* Residual deviance.
# Degree of freedom.
} Akaike information criterion.
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number of men reaching an older age which may con-
tribute to the disease becoming more frequently diag-
nosed [33].
The age-standardised mortality rates declined in the
later periods for all three countries. From our results,
mortality rates for Geneva declined steadily from 1973
onwards whereas for Singapore there was a steady rise
in mortality rates from 1968 to 1992 with a recent de-
cline from 1993 onwards. This raises the question of
whether this could be an effect of PSA testing. To date
there is little conclusive evidence that PSA-based screen-
ing reduces prostate cancer mortality. However, recent




Model Res Dev* Df# AIC} P-value Res Dev
Age (A) 13.5 42 402 0.999 1.1079
Age-Drift (AD) 13.3 41 404 0.999 1.1077
Age-Period (AP) 8.7 36 409 0.999 0.71
Age-Cohort (AC) 6.9 30 419 0.999 0.50
Full APC 5.0 25 428 0.999 0.28
Likelihood ratio test
Model (H0vs H1) Dev DF P-value Dev
AP vs APC 3.7 11 0.979 0.43
AC vs APC 1.9 5 0.869 0.22
* Residual deviance.
# Degree of freedom.
} Akaike information criterion.results. The Prostate, Lung, Colorectal, and Ovarian
(PLCO) Cancer Screening Trial in the US showed a mar-
ginal increase in the incidence and concluded that there
was no mortality reduction with combined PSA and
digital rectal examination screening over an 11 year me-
dian follow-up [34]. The UK based European Rando-
mised Study of Screening for Prostate Cancer (ERSPC)
trial after a median follow-up of 11 years showed an
increased incidence and a 21% relative reduction in risk
of death that was only marginally statistically significant
at p = 0.001 [35].
Treatment of prostate cancer does not differ greatly
between the three countries yet the mortality rate is de-
clining much faster in Singapore and Geneva comparedrates in Singapore, Sweden and Geneva
Sweden Geneva
(Negative binomial) (Poisson)
DF AIC P-value Res Dev DF AIC P-value
42 641 0.999 72.0 42 282 0.003
41 643 0.999 40.4 41 252 0.495
36 653 0.999 32.4 36 254 0.642
30 665 0.999 34.1 35 263 0.512
25 674 0.999 27.6 30 267 0.594
DF P-value Dev DF P-value
11 0.999 4.8 6 0.570
5 0.999 6.5 5 0.258
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be explained by genetic differences in the populations,
different environmental factors or a combination of both
(gene-environment interactions) [36]. Alternatively, it
may argued that the drop in mortality is due to techno-
logical advancements in diagnosis and treatment of the
disease, such as newer surgical approaches for localized
disease, improved irradiation techniques and hormonal/
antiandrogenic therapy [11], or due to a combination of
all these factors. The relatively sharper drop in mortality
rate in Geneva may be due to the adoption of hormonal
therapy [18].
From the APC modeling, the incidence and mortality
rates of prostate cancer appeared to be more strongly
associated with the age and period effect than with the
birth-cohort effect in all three countries, based on the
lower calculated AIC criteria and likelihood ratio test
results. Older males tended to be at higher risk of develop-
ing prostate cancer and in the later periods. In addition,
mortality was higher in older males and across the earlier
periods, which could be confounded by PSA testing. Males
of older age and in the later period of diagnosis had a
higher incidence, whereas males of older age and in the
earlier period had higher mortality rates for prostate
cancer.
A limitation of this study was that it extended over a
relatively long time period during which changes in diet,
environmental and diagnostic factors are likely to have
occurred. It would be a further challenge to identify the
independent factors influencing the change in the trends
of incidence and mortality as it could be due to individ-
ual factors acting independently or in combination. Age-
standardized rates for incidence and mortality in our
study are not comparable with other published data as
different weightings were used. Accurate interpretation
of the incidence and mortality trends in the three coun-
tries would be incomplete without data on PSA screen-
ing as a potential confounder. As data on individual PSA
testing was not available, it was not possible to separate
the effect of the real increment in incident cases from
over-diagnosis due to increased screening, as we would
need to establish whether patients had PSA screening
prior to diagnosis.
Conclusion
Our analysis showed that overall age-standardised inci-
dence rates of prostate cancer increased over the period
1973 to 2006 and that the mortality rates declined over
the later period (1998 to 2006) in all three countries.
Both incidence and mortality rates were much lower in
Singapore than in Sweden and Geneva. The mortality
rates for Singapore followed an inverted U-shape
whereas the mortality rates for Sweden remained rela-
tively unchanged and Geneva experienced a steadydecline over the period 1973 to 2006. Based on APC
modeling, the age and period effects were shown to be
more strongly associated with incidence and mortality
than the birth cohort effect.
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